















Radical cystectomy, with a pelvic lymph-node 
dissection, is widely regarded as the ‘reference 
standard’ treatment for invasive bladder 
cancer [1]. Survival after cystectomy is 
predicted by the pathological stage of the 
primary bladder tumour and nodes, as well as 
the quality of cystectomy [2]. Chemotherapy 
may improve the subsequent survival [3], but 
even with combined therapy the quality of 
surgery influences the outcome. For example, 
a subset analysis of a randomized, 
cooperative group trial of neoadjuvant 
chemotherapy plus cystectomy showed that 
the surgical factors of margin status, extent of 
node dissection, number of nodes resected 
and individual surgeon’s experience (by 
training and volume) were independent 
predictors of overall survival [4]. Neoadjuvant 
chemotherapy was more likely to improve the 
survival of patients with muscle-invasive 
bladder cancer if they received a high-quality 
operation by an experienced surgeon. Despite 
mounting evidence that the quality of surgery 
matters, there are no universally accepted 
standards for radical cystectomy and pelvic 
node dissection, because the quality of 
surgery varies widely among individual 
surgeons and patients
What constitutes an adequate radical 
cystectomy and pelvic node dissection for 
bladder cancer? What benchmarks can be 
used to define the quality of surgery in an 
individual patient? We attempted to derive a 
set of standards for radical cystectomy and 
node dissection by compiling the inclusive 
cystectomy experience of 16 surgeons 
operating on 1091 cases over 3 years 
(2000–2002) from four centres experienced 
in treating bladder cancer [5]. Participating 
surgeons performed cystectomy for cure or 
palliation in ‘all comers’, regardless of age 




1% of patients for health reasons. Our 
collaborative surgical results reflect, as much 
as possible, what cystectomy can achieve in 
unselected patients presenting with diverse 
clinical situations.
We evaluated surgical and pathological 
features defined by radical cystectomy and 
pelvic node dissection among patients of 
varying ages, health states, clinical stages of 
bladder cancer, and previous treatments 
(pelvic surgery, chemotherapy and radiation 
therapy) for bladder or other pelvic malignant 





75 years and 20% were 
octogenarians; 16% had been treated 
previously. Half had advanced pelvic disease 
(pT3–4) and 20% had positive lymph nodes. 
Surgical endpoints included soft-tissue 
margin status, extent of pelvic node 
dissection, number of nodes examined and 
individual surgeon volume.









100. There was no significant difference 
between surgeons or institutions in the 
surgical quality or type of patient operated, 
except the surgeons with the highest volume 
tended to operate on more elderly, sicker, and 
pre-treated patients than surgeons with 
lower volumes. Surgeons used a standard or 
extended bilateral node dissection in 80% of 
patients and 20% had a limited (9%) or no 
node dissection (11%). A limited node 




75 years and in half receiving previous 
extensive pelvic treatment. A standard node 
dissection was sometimes impractical if the 
operation had to be completed quickly in 
infirm patients, or was impossible because of 
previous pelvic surgery, chemotherapy or 
radiation.
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Table 1 shows the surgical outcomes of 
margin status, extent of node dissection and 
average node counts, accounting for patient 
variability. Although the overall positive 
margin rate was 6.5%, margins were positive 
in 12% of patients with locally advanced 
disease. Older, and pre-treated, patients had 
less extensive node dissections and lower 
node counts than younger, healthier patients 
who had not received previous pelvic therapy. 
The mean (median) number of nodes 
examined for all patients was 12.5 (11), but 
varied widely among individual patients 
having anatomically similar node dissections. 
This variability could be from anatomical 
differences between individuals or could 
reflect differences in the method of 
pathological review. Using such benchmarks, 
we think that experienced surgeons who 
regularly perform cystectomy (at least 10 per 





90% of cases and remove a mean 
of 10–14 nodes, recognizing that such 
standards will not be met in some of the most 
difficult cases.
Last, the issue of standards raises two 
questions. First, with so many variables to be 
counted, can acceptable and clinically useful 
standards for cystectomy be established at 
all? We think that general guidelines can be 
proposed, based on robust data combined 
from many institutions and surgeons 
performing cystectomy in largely unselected 
patients, rather than the experience of one 
surgeon. Surgeons are accountable for 
surgical margins, extent of node dissection 
and nodes because they are proxy measures 
of surgical quality correlating with bladder 
cancer outcome.
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Second, are surgical standards important? We 
think they are for the outcome in individual 
patients, and for the design and evaluation of 
multimodal studies in bladder cancer. Who, 
where and how well surgery is performed 
could influence follow-up care, including 
adjuvant therapies. Recognized and accepted 
standards might also serve to elevate the 
overall quality of cystectomy in the future. 
This alone may prove to be as or more 
important than anticipated improvements in 
chemotherapy.
The practical issues involved in creating 
uniform standards for cystectomy can be 
formidable but are clearly surmountable. It is 
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Standards of radical cystectomy and pelvic node dissection, using data from the Bladder Cancer 




















No Yes No Yes
No. of patients 709 104 213 65
Positive margins, % 6 9.5 5.5 3
Standard/extended node dissection, % 90 65 76 40
Mean nodes 14 8 10 6
 
It is generally accepted that the presence of 
seminal vesicle invasion (SVI) in a resected 
specimen is an unfavourable prognostic 
factor in prostate cancer [1–3]. SVI has been 
reported in 5–13.6% of recent radical 
prostatectomy specimens [4–6]. Various 
studies have assessed the prediction of 
recurrence and prognosis in patients with 
prostate cancer and SVI treated by radical 
prostatectomy. In these studies, factors 
influencing prognosis have been identified 
by retrospective analysis, and include 
preoperative PSA level, age, Gleason score 
(biopsy and resected specimen) and 
percentage of cancer in biopsy specimens 
[7–11].
In refining these criteria, Ramsden and 
Chodak [12] described a significant 
improvement in prognosis for men with SVI if 
the histology showed negative margins, 
unilateral SVI or perineural invasion. They 
concluded that this may be applied to patients 
with SVI to direct adjuvant therapy and guide 
postoperative counselling.
At the other end of the prognostic spectrum, 
what should the surgical approach be with 
regard to the SVs? It has been suggested that 
predicting SVI before surgery would enable 
surgeons to develop a SV-sparing 
prostatectomy, in the belief that this may 
reduce morbidity. It has been argued that 
preserving the SVs may result in less 
dissection close to the neurovascular bundle, 
with a theoretically lower risk of damaging it. 
It still has to be determined whether 
extirpation of the SVs changes the outcome. 
Some argue that SVI is the harbinger of 
metastatic disease, and therefore that any 
radical local treatment is destined to fail if SVI 
is present.
There are several counter-arguments; after 
the prostate has been removed the SVs serve 
no known purpose, and that the higher risk to 
the neurovascular bundle might be from 
dissection around the prostatic apex, rather 
than during SV dissection. In addition, there is 
a risk of leaving undetected carcinoma from 
isolated metastasis to the SV tip, even if the 
cut margins of the amputated SV are free 
from tumour. Type 3 SVI (isolated metastasis) 
is found in 13% of specimens containing SVI 
[13].
The current approach by some British 
surgeons is partial amputation of the SVs, as 
opposed to complete excision. This permits 
some pathological assessment of SVI, 
allowing an evaluation of the prognosis. 
Traditionally, unlike lymph node sampling, it 
was thought that resecting the SVs was of 
therapeutic rather than diagnostic value. It is 
likely that tumour metastasis to the tip of the 
SV would be missed by this technique. 
However, it is unlikely that SV dissection 
would be therapeutic if SVI is present.
Unfortunately SVI is still difficult to predict 
before surgery by imaging, a DRE or SV biopsy 
in patients with localized prostate cancer 
[14–18]. A trial involving patients with similar 
preoperative potency, randomized to partial 
or complete excision of the SVs, might be of 
interest. However, until clinicians are able to 
 








confidently predict patients at low risk of 
SVI before surgery with a guarantee of 
oncological safety, the current practice of 
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Prostate specific antigen density of 
the transition zone for predicting 
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cancer in patients with serum prostate 

















Prognostic significance of preoperative 
factors in localized prostate carcinoma 
treated with radical prostatectomy: 
importance of percentage of biopsies that 
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 Seminal vesicle involvement 
after radical prostatectomy: predicting 
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TCC of the ureter and renal pelvis is relatively 




5% of all cases 
of urothelial neoplasia. The standard 
treatment has been nephroureterectomy with 
excision of a cuff of bladder. The idea of 
organ-sparing surgery was first reported 
in 1945 for ureteric tumours [1]. With 
developments in endoscopic and 
percutaneous techniques, organ-sparing 
surgery is feasible in patients with inadequate 
renal reserve, at high risk of bilateral disease, 
or with significant comorbidity. Organ-
sparing surgery is also suited to patients with 
low-grade disease and a normal contralateral 
kidney, because these lesions have a low risk 





[2] reported a median survival of 66.8 months 
for patients with low-grade vs 14.1 months 
for those with high-grade disease. In 83% of 
these patients, low- and high-grade tumours 
matched low- and high-stage disease. 
Percutaneous treatment is possible when 
the ureteroscopic approach is difficult. 
Inaccessible infundibulo-calyceal tumours or 
large pelvic tumours are more readily treated 
by the percutaneous approach. This route may 
be necessary in patients where retrograde 
access is difficult because there are 
anatomical anomalies.
With more conservative treatment it was 
reported that the ipsilateral recurrence rate is 
high (a third) but there were few patients 
in the study (14) and the follow-up was 2–11 
years [3]. To minimize the risk of recurrence 
and because of the success of intravesical 
agents in the treatment of superficial TCC of 
the bladder, several reports have investigated 
their role in adjuvant treatment after organ-
sparing surgery of the upper tracts. BCG 
therapy has been most commonly used but 
other agents, including mitomycin C, thiotepa, 
 












 have also been 
tried. The agent can be instilled directly 
through a nephrostomy tube after the 
position has been checked by imaging, to 
prevent obstruction or extravasation. The 
agent is instilled via gravity and linked to a 
manometer so that the intrarenal pressure 




O [4]. Alternatively, it 
may be given retrogradely via a ureteric 
catheter, by bladder instillation with the 
patient in the Trendelenberg position after 
inserting a ureteric stent, or via a urethral 
catheter in a patient with VUR [5].
Unfortunately, the results of intravesical 
treatment are varied. Herr [6] reported on a 
patient with a single kidney and a pT2G3 




 at the PUJ. After pelvectomy, 
ureterectomy and autotransplantation the 
patient received six weekly courses of 
intravesical BCG. Thirteen months after 
surgery the patient was free of recurrence and 
had negative cytology. A report by Orihuela 
and Smith [7] found an 80% recurrence rate 
in patients who did not receive adjuvant BCG, 
vs 17% among those who did. However, a 
follow-up study showed no survival 





 [9] used Pasteur BCG in 10 renal 
units (eight patients) with cytological 




. In all but one 





 [10] of 42 upper 
tracts treated solely by endourological means 
gave a recurrence rate of 24%. After 
intravesical adjuvant BCG or mitomycin C the 
recurrence rate was 12.5% and 14%, 





 [11] reported on 10 patients 
with solitary kidneys and upper tract TCC; the 
patients received an intravesical BCG 
instillation as an adjunct to percutaneous 
resection, with no reported morbidity. Six of 
the patients had no recurrence, one had 
recurrence at 19 months, and one developed 
metastases at 15 months. One died from 
disease progression. Further studies using 
topical BCG after organ-sparing surgery are 
listed in Table 1 [12–16].
Mitomycin C is a cross-linking agent and 
in part inhibits DNA synthesis. Topical 
mitomycin C is well tolerated in the upper 
urinary tract and there are no reports of 





 [17] reported on two patients with 
bladder cancer and VUR who developed lower 
ureteric recurrences. They received 
intravesical treatment for 18 months, and 
after 2 years they were reported to be 
disease-free. Eastham and Huffman [4] 
reported on the use of mitomycin C as topical 
therapy after endoscopic resection of 
superficial TCC of the renal pelvis or ureter. 
Seven patients were treated over a 4-year 
period and were either not fit for more 
aggressive treatment or had a solitary kidney. 
Five patients had no evidence of disease 
whilst one had a marked decrease in tumour 
burden. Table 1 also shows other studies 
using mitomycin C [4,18].
After radical cystectomy, 2.4–8.5% of patients 
develop upper tract TCC [19]. Factors 
associated with a greater risk of recurrence 





, and TCC in the 
prostatic urethra and distal ureter [20]. 
Recurrence in the upper tract after 
cystectomy is usually aggressive and has a 
poor prognosis. The treatment of choice is 
nephroureterectomy but in patients with 
bilateral disease or a solitary kidney, and low-
grade/low-stage disease, conservative 
treatment has been used; whilst the results 
appear encouraging, the follow-up is short 
and patients few [21].
Upper urinary tract tumours are rare and the 
most appropriate treatment for low-grade 
tumours is not entirely clear. The results 
appear encouraging but no individual study 
has shown a statistical improvement in 
survival and recurrence rates. What is known 
about intravesical chemotherapeutic and 
immunological treatments after conservative 
surgery is from retrospective studies with 
small cohorts of patients and with 
heterogeneous characteristics. The reasons 
for inconclusive results include; (i) too few 
patients to show clinical significance; (ii) 
inadequate contact time between the 
urothelium and the agent being instilled; and 
(iii) possible differences between upper tract 
tumours and bladder tumours. Large 
prospective multicentre studies are needed to 
clarify the situation. Meanwhile, ablative 
surgery remains the standard for managing 
upper tract TCC but in circumstances where 
this may be problematic, conservative 
resection with adjuvant topical 
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TABLE 1 Studies using adjuvant topical BCG or adjuvant mitomycin C after organ-sparing surgery
Ref N patients Regimen Tumour stage/grade Recurrence rate (%) Follow-up, months
BCG
[12] 17 Retrograde Ta/T1/CIS/G2–G4 28.5 11–64
[13] 14 Percutaneous NG 12.5 NG
[14] 13 Percutaneous Ta/G1–G2 13 6–36
[15] 8 Percutaneous NG 12.5 9–59
[16] 9 Retrograde NG 22 4–41
Mitomycin C
[4] 7 Percutaneous NG 28.5 1–12
[18] 20 Retrograde G1–G3 54 30
NG, not given.
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RED-CELL SALVAGE IN UROLOGICAL SURGERY REBECCA S. HAMM, 
MARK DAUGHERTY and MALCOLM C. CRUNDWELL – Department of Urology, Royal 
Devon and Exeter NHS Trust, Exeter, Devon, UK
Significant blood loss during major urological 
surgery is common and in the UK is usually 
replaced by transfusion of donated 
homologous blood. This is not always entirely 
satisfactory because of the increasingly 
limited availability and the well-documented 
risks associated with homologous blood 
transfusion. Most recently concerns have 
been raised about possible contamination of 
donated blood with variant Creuzfeldt-Jakob 
disease [1] which has caused the Blood 
Transfusion Service to discontinue donations 
from those who have received a blood 
transfusion since 1 January 1980. This is likely 
to have a significant affect on the stocks of 
donated blood and means that alternatives to 
homologous blood transfusion should be 
actively pursued.
Autologous blood transfusion is the collection 
of blood from an individual for the purpose of 
re-infusion into the same individual at a later 
time. Autologous blood transfusion can be in 
the form of preoperative autologous blood 
donation (PABD), intraoperative cell salvage 
(IOCS) or postoperative cell salvage and acute 
normovolaemic haemodilution (ANH).
The first PABD was described in 1921 by F.C. 
Grant in a patient undergoing surgery for a 
cerebellar tumour. PABD became standard 
medical practice in the 1920s and 30s and 
was frequently used by Cushing during 
cranial surgery. It was not until World War II 
that transfusion practice changed and 
homologous products became readily 
available.
Cell salvage with direct reinfusion was 
described in haemothorax cases in 1931 by 
Brown and Debenheim. In 1943 Arnold 
Griswold developed the first cell salvage auto-
transfusion device, collecting blood in a bottle 
by suction, straining it through a cheese cloth 
and then re-infusing it. Modern cell salvage 
techniques still use this basic principle.
In ANH, 1–3 units of whole blood are drawn 
from the patient after the onset of 
anaesthesia and the volume is replaced with 
colloid or crystalloid volume expanders. Any 
blood lost during surgery is therefore more 
dilute and the withdrawn blood can be re-
infused at the end of the procedure.
In modern cell salvage techniques (IOCS) 
salvaged blood is aspirated from the surgical 
field, anticoagulated in the suction device and 
then collected in a sterile collection container. 
When an adequate amount of blood has been 
collected it is pumped into a spinning 
centrifuge bowl. Red cells, being the heaviest 
components of blood, collect at the lowest 
point in the bowl and supernatant containing 
the other components of blood spill over into 
a waste bag. Sterile saline solution is pumped 
through the spinning centrifuge bowl and 
displaces the lighter remaining contaminants. 
Once this process is complete the red blood 
cells are re-suspended and can be transfused, 
usually immediately, or can be stored under 
specific conditions for up to 6 h.
IOCS has become the mainstay of many 
general surgical operations where there is a 
large volume blood loss, e.g. ruptured aortic 
aneurysm repair, greatly reducing the need for 
homologous blood transfusion. However, 
there has been concern that IOCS is not safe 
in the presence of malignant disease, because 
malignant cells may spill into the operative 
C O M M E N T S
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field, be taken into the cell salvage machine, 
and because they are heavy like red cells, 
returned to the patient. The use of leukocyte 
depletion filters can reduce the risk of such 
occurrence but concerns remain as to 
whether use of IOCS may compromise 
surgical cure. Malignant cells have been 
found in the circulation during surgery 
even when IOCS is not used [2], but the 
significance of these circulating cells is 
not clear. If re-infused cells were clinically 
significant it would be expected that patients 
having had IOCS might present with early 
widespread metastases, or at least unexpected 
lung metastases. This has not proven to be 
the case in bladder, renal or prostate 
cancer. The four reports in Table 1 [3–6] 
illustrate experience of nearly 250 cases of 
IOCS, with no cases of early unexpected 
metastasis.
Since 1996 it has been the policy in our unit 
to have IOCS available at all major open 
urological surgery. We have experience of 
>150 cases, including 74 cystectomies, 30 
radical nephrectomies and 37 radical 
prostatectomies, and have transfused over 
600 units of salvaged blood. There have been 
no cases of early lung or diffuse metastases 
suggestive of spread of malignant disease by 
IOCS.
The theoretical risk of metastatic spread 
secondary to IOCS has not become apparent, 
although the very real risk of spread of viral 
infection and other complications of 
homologous transfusion remain.
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TABLE 1 Reports of IOCS in urology
Ref Date N patients Operation Outcome Comment
[3] 1986 24 RC Two died from local recurrence, LN met IOCS is safe
10 RP One pelvic recurrence
13 RN Two lung metastases





[5] 2003 87 RP No difference in outcome for IOCS over
pre-donation or no transfusion
IOCS is safe
[6] 2001 62 RP No difference in progression-free survival






RC, RP, RN, radical cystectomy, prostatectomy, nephrectomy.
